Approved for use through 04/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) JANS-0075/JAB1721USPCT
In re Application of: Jose Ignacio Andres-Gil, et al.	
Application No.: 10/524,197	
Filed: February 10, 2005	
For: C-Substituted Tricyclic Isoxazoline Derivatives And Their Use As Anti-Depressants	
except as provided below, the terminal part of the statutory term of any patent granted on the instant	prior patent is defined in 35 U.S.C. 154 owner hereby agrees that any patent so prior patent are commonly owned. This
In making the above disclaimer, the owner does not disclaim the terminal part of the term of any paten would extend to the expiration date of the full statutory term as defined in \$5 U.S.C. 154 and 173 of the patent is presently shortened by any terminal disclaimer," in the event that said prior patent later: expires for failure to pay a maintenance fee; is held unenforceable:	
is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened in the contract of the country term as presently shortened.	ov any terminal disclaimer.
	-,,
Check either box 1 or 2 below, if appropriate. 1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university etc.), the undersigned is empowered to act on behalf of the business/organization.	r, government agency,
I hereby declare that all statements made herein of my own knowledge are true and that a belief are believed to be true; and further that these statements were made with the knowledge that made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United statements may jeopardize the validity of the application or any patient issued thereon.	willful false statements and the like so
The undersigned is an attorney or agent of record. Reg. No. 51,430	
/Stephanie A. Barbosa/ Signature	April 14, 2008 Date
Signature	Date
Stephanie A. Barbosa	
Typed or printed name	
	215-568-3100 Telephone Number
✓ Terminal disclaimer fee under 37 CFR 1.20(d) included.	
WARNING: Information on this form may become public. Credit card inform be included on this form. Provide credit card information and authorization	ation should not on PTO-2038.
'Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO Institutes on all interfacions of interfacions is required by 3° CVPT 1.54.1 in the interfacion of regions of regions of a scientific by the public which is to the quite by the opposition of the public by covered by 5° U.S. Ct. 22 and 5° U.S. 1.1.1 and 1.14. This collection is estimated to be the 2° Initiatives to complete including gathering preparing, and submitting is opposed by 5° U.S. Ct. 22 and 5° U.S. 1.1.1 and 1.14. This collection is estimated to be the 2° Initiatives to complete including gathering preparing, and submitting is opposed by 5° U.S. 1.1.1 and 1.14. This collection is estimated to be the 2° Initiatives to complete including gathering preparing and submitted in the complete gathering prepared in the property of the prop